{"schema_version":"secwatch.filing_event.v1","accession":"0001567264-24-000042","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.569123+00:00","generated_at":"2026-05-31T10:54:35.662911+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Intensity Therapeutics doses first patient in Phase 3 sarcoma trial; cash $6.3M into Q1 2025","bullets":["First patient dosed in Phase 3 INVINCIBLE-3 study of INT230-6 vs SOC in soft tissue sarcoma; plans 333 patients.","Collaboration with SAKK for Phase 2 INVINCIBLE-4 study in early-stage triple-negative breast cancer; start Q3 2024.","Net loss $5.0M in Q2 2024 vs $3.7M in Q2 2023; R&D expenses $3.6M (up from $0.9M).","Cash, cash equivalents and marketable debt securities $6.3M as of June 30, 2024.","Appointed Thomas Dubin, J.D., MPH to board of directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001567264-24-000042","json":"https://secwatch.observer/filing/0001567264-24-000042.json","markdown":"https://secwatch.observer/filing/0001567264-24-000042.md","text":"https://secwatch.observer/filing/0001567264-24-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000156726424000042/0001567264-24-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000156726424000042/intensity-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:54:35.662911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}